# Engrail Therapeutics

Engrail Therapeutics is an Asset Manager based in San Diego, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** 12750 High Bluff Drive Suite 190, San Diego, CA 92130, United States
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** engrail.com
- **LinkedIn:** https://www.linkedin.com/company/engrail-therapeutics

## Regulatory record

- **Reports private funds:** No

## About

Transforming the lives of patients with life-limiting diseases of the nervous system | We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

## Sectors

- Neuroscience
- Biotechnology
- Pharmaceuticals

## People

- Vikram Sudarsan — President and Chief Executive Officer
- Kimberly Vanover — Chief Scientific Officer
- Paul Cayer — Chief Financial Officer
- Stephen Cunningham — EVP, Research & Development and Chief Development Officer
- Peter Bisgaard — Chairman of the Board

## Questions

### Who leads investment decisions at Engrail Therapeutics?

Engrail is led by CEO Vikram Sudarsan, a neuroscientist and former CEO of Cipla Technologies. The board includes representatives from its venture investors, including Peter Bisgaard (Pivotal Life Sciences), Tiba Aynechi (Norwest Venture Partners), Jasper Bos (Forbion), Heath Lukatch (Red Tree Venture Capital), and Niall O’Donnell (RiverVest). The firm's R&D strategy is overseen by Chief Development Officer Stephen Cunningham, a co-founder (per firm website).

### What does Engrail invest in?

Engrail develops therapeutics for neurologic, neuropsychiatric, and neurodevelopmental disorders. Its pipeline includes ENX-102 (generalized anxiety disorder), ENX-104 (dysthymic disorder), ENX-203 (social anxiety disorder), ENX-205 (a neurodevelopmental disorder), and an undisclosed candidate. The firm uses internal discovery and external partnerships to build its pipeline (per firm website).

### Does Engrail make direct investments or fund commitments?

Engrail is not an investment firm; it is a drug development company. It does not make fund commitments or direct investments in other companies. Its capital is deployed into R&D for its own pipeline (per firm website).

### What investment stages does Engrail target?

Engrail is a clinical-stage company, meaning it targets drug candidates that have advanced from preclinical discovery into human clinical trials. Its active programs are in Phase 2 trials (per firm website).

## Related profiles

- [Premise Health Inc.](https://altss.com/profile/premise-health-inc)
- [Value Asset Management](https://altss.com/profile/value-asset-management)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/engrail-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology